Zydus Cadila receives final approval from USFDA for Ezetimibe Tablets

13 Jun 2017 Evaluate

Zydus Cadila has received final approval from The US Food and Drug Administration (USFDA) to market Ezetimibe Tablets USP, 10 mg. Ezetimibe is a drug used to reduce high cholesterol levels. It will be produced at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The estimated sales for Ezetimibe Tablets is $2.7 billion, as per IMS MAT April 2017.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.


Zydus Lifesciences Share Price

881.95 -2.90 (-0.33%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×